In summary, we provide evidence that the anti-inflammatory effects of AZM may be contributed to via an increase in the bacterial uptake by CF MDMs, increasing the proportion of CF MDMs able to polarize into the inflammation-resolving M2 phenotype and increasing the secretion of the anti-inflammatory cytokines IL-10 and CCL18. The gene discussed is CCL18; the disease is cystic fibrosis.